Attana Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Teodor Aastrup

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	11.9%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Teodor Aastrup (53 yo)

less than a year

Permanencia

Dr. Teodor Aastrup, Ph D., is a Co-Founder and Director of Attana AB and served as its Chief Scientific Officer since September 2023 until 2024 and served as its Chief Executive Officer since 2024. Dr. Aas...

Attana Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

Attana Announces CEO Changes

No independent directors

No independent directors

Chairman of the Board recently bought kr90k worth of stock

Recent updates

Full year 2023 earnings released: kr0.051 loss per share (vs kr0.07 loss in FY 2022)

New minor risk - Shareholder dilution

No independent directors

Attana Announces CEO Changes

The Swedish Knowledge-Foundation Grants SEK 12 Million to Project Concerning Individual Immunity Profiles for Diagnostics and Medical Development Based on Attana's QCM Technology

New major risk - Revenue size

Full year 2022 earnings released: kr0.07 loss per share (vs kr0.081 loss in FY 2021)

Attana AB Submits International Patent Application

Attana AB has completed a Follow-on Equity Offering in the amount of SEK 11.4 million.

Attana Submits New Patent Application Regarding Neutralizing Effect in Complex Samples

Third quarter 2022 earnings released

Price target increased to kr1.15

No independent directors

Price target decreased to kr1.05

No independent directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Attana Submits New Patent Application

Chairman of the Board recently bought kr90k worth of stock

Third quarter 2021 earnings: Revenues exceed analyst expectations

Second quarter 2021 earnings released

Attana Obtains CE-IVD Marking for Its First Products Within Clinical Diagnostics

First quarter 2021 earnings released: kr0.017 loss per share (vs kr0.017 loss in 1Q 2020)

Attana AB Announces Approval and Initiation of Clinical Phase I/II Study for the New COVID-19 Vaccine

Attana Collaborates with Linnaeus University Toaccelerate the Development of Unique Antibody Tests for COVID-19

New 90-day low: kr1.30

Attana Completes FDA Medical Device Class 1 Listing and Facility Registration

Attanas Record Publishes in IBI Shows Extraordinary Results

Attana Receives Contract Research Order from Global Pharma Company

Third quarter 2020 earnings released: kr0.013 loss per share

New 90-day low: kr1.46

Attana Submits A New Patent Application

First half earnings released

CEO

Permanencia